Answers are grounded in this paper and cite their sources.
We describe a patient who underwent a successful heart and kidney transplant for light-chain amyloidosis. She had an excellent hematologic response to bortezomib/dexamethasone therapy. Follow-up therapy with lenalidomide was started, and the patient quickly had a fatal allograft rejection of the heart and kidney. We present evidence to support the theory that lenalidomide, a known immunomodulator, may have stimulated the immune system and precipitated the fatal rejection episode.
No takes yet. Share an insight, caveat, or question.
Meyers et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: